Navigation Links
Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
Date:5/19/2009

SAN DIEGO, May 19 /PRNewswire/ -- Cylene Pharmaceuticals, Inc., announced today that it will present major advances in the development of their first-in-class, CK2 inhibitor CX-4945 at the 2009 BIO International Convention on Wednesday, May 20th at 4:40 pm. William G. Rice, Ph.D., Cylene's president and CEO, will discuss the mechanism, antitumor properties and tumor selectivity of CX-4945, the Company's oral protein kinase inhibitor currently in Phase I clinical trials. This proprietary compound has demonstrated promise as a potent and selective oral inhibitor of protein kinase CK2, a previously unexploited molecular target with well documented roles in many cancers, indicating broad therapeutic potential. Cylene's Serine/Threonine Kinase Inhibitor program has also delivered orally active pan-PIM inhibitors of the PIM-1,2,3 kinases, still in pre-clinical development.

Cylene Pharmaceuticals, Inc. is a Phase II-stage, small-molecule Oncology Company designing promising therapeutic agents with its two proprietary product discovery platforms, using novel chemistry and biology capabilities. The company was co-founded by Daniel Von Hoff, MD, one of the world's leading oncology clinical investigators. In addition to the CK2 inhibitor CX-4945, Cylene's Nucleolus Targeting Technology has generated Quarfloxin (CX-3543), a small molecule agent that is in Phase II development for the treatment of carcinoid/neuroendocrine tumors (C/NET). Quarfloxin disrupts an essential protein: DNA complex in cancer cells, thereby knocking out a critical source of support for tumor cells and selectively causing cancer cell death. Quarfloxin is safe and well-tolerated and has completed two separate Phase I trials on different dosing schedules, during which biological activity was observed in several C/NET patients. More information can be found at www.cylenepharma.com.


'/>"/>
SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... - Cincinnati, Ohio (PRWEB) , ... December 09, ... ... the production of miniature, folded, pharmaceutical inserts and outserts. As a means ... Device. This addition will enable Flottman to individually code professional inserts (PIs) ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund announced Thursday ... recommending the film Whispering Spirits and its discussion guide for use by ... education tool in the war against teen drug abuse. NCADD is the oldest ...
(Date:12/9/2016)... ... 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill the ... amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It eliminates ... be set up in a matter of minutes, or even seconds. The SAFETY STRAP ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name ... New York, NY, on December 3rd, to benefit Holy Name Medical Center's programs ... event, which raised over $1 million - the largest event in the Center's ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to ... "I thought that if the nebulizer had a more child-friendly design, then children would ... He developed the patent-pending NEBY to avoid the need to deliver medication via a ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... -- Research and Markets has announced the addition of the ... to their offering. ... report also analyses the market by the following Technology Types: Label-Free Technology, ... US, Canada , Japan , ... America , and Rest of World. Annual estimates ...
(Date:12/9/2016)...  Harmar Mobility, LLC announced today that Steven E. Dawson has been ... of Directors. Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing ... of industries. He brings to the company deep operational and leadership expertise, ...
(Date:12/9/2016)... Texas , Dec. 9, 2016  RxWiki Inc., ... apps, and digital marketing strategies of thousands of pharmacies ... it won Austin Inno,s "50 on Fire" ... "We,re pleased to accept the award as ... Loughlin , Chief Executive Officer at RxWiki. "Our platform ...
Breaking Medicine Technology: